Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718425 | 0.82 | KIF11 (0.36) | KIF11CYP2C19HIF1ACNR1CNR2 | |
| SCHEMBL285289 | 0.80 | POLB (0.41) | KIF11ELANECYP2C19HIF1ACHRM2 | |
| SCHEMBL295983 | 0.77 | TDP1 (0.45) | KIF11ELANECYP2C19HIF1ACHRM2 | |
| SCHEMBL716371 | 0.77 | CYP2C19 (0.37) | KIF11ELANECYP2C19HIF1ACHRM2 | |
| SCHEMBL285400 | 0.76 | TDP1 (0.47) | KIF11ELANECHRM2CHRM4CHRM1 | |
| SCHEMBL719627 | 0.76 | KDM4E (0.37) | KIF11CYP2C19HIF1ACNR1CNR2 | |
| SCHEMBL285578 | 0.75 | TDP1 (0.49) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL17891299 | 0.73 | MMP12 (0.50) | ELANECNR2KMT2A | |
| SCHEMBL17511150 | 0.72 | ALDH1A1 (0.42) | ELANEKMT2A | |
| SCHEMBL716724 | 0.71 | NPC1 (0.48) | KIF11CYP2C19HIF1ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729203-B2 | Polymer composition | CONTAMAC LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| US-20120053313-A1 | POLYMER COMPOSITION | CONTAMAC LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053313-A1 | POLYMER COMPOSITION | UACA, CRYAA, CRYZ | KIF11 519/4885ELANE 4130/4885KCNH2 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.